{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:03Z","timestamp":1792533603336,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["20-75-10132"],"award-info":[{"award-number":["20-75-10132"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e26362","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T09:19:34Z","timestamp":1708075174000},"page":"e26362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7987-2017","authenticated-orcid":false,"given":"Tamara","family":"Tyrinova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egor","family":"Batorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Aristova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Ushakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Sizikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Denisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chernykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e26362_bib1","doi-asserted-by":"crossref","DOI":"10.4110\/in.2021.21.e21","article-title":"Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad","volume":"21","author":"Ge","year":"2021","journal-title":"Immune Netw."},{"key":"10.1016\/j.heliyon.2024.e26362_bib2","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1002\/jcp.26075","article-title":"Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis","volume":"233","author":"Safarzadeh","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00327","article-title":"Myeloid-derived suppressor cells in sepsis","volume":"10","author":"Schrijver","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2018.09.001","article-title":"The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process","volume":"48","author":"Salminen","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.heliyon.2024.e26362_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000168","article-title":"Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets","volume":"3","author":"Bizymi","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.heliyon.2024.e26362_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1189\/jlb.4RI0515-204R","article-title":"Transcriptional regulation of myeloid-derived suppressor cells","volume":"98","author":"Condamine","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e26362_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e26362_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"218","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e26362_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103599","article-title":"Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers","volume":"21","author":"Lim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e26362_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01147","article-title":"The CD14 + HLA-DR lo\/neg monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy","volume":"10","author":"Mengos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2024.e26362_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092614","article-title":"High M-MDSC percentage as a negative prognostic factor in chronic lymphocytic leukaemia","volume":"12","author":"Zarobkiewicz","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e26362_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0491-y","article-title":"Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"7","author":"Lee","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.heliyon.2024.e26362_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e26362_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215459","article-title":"Monocytic myeloid derived suppressor cells in hematological malignancies","volume":"20","author":"Palumbo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e26362_bib22","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8507","article-title":"Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients","volume":"7","author":"Marini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e26362_bib23","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ajh.23865","article-title":"Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation","volume":"90","author":"Lv","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102050","article-title":"The role of myeloid-derived suppressor cells (MDSCs) in graft-versus-host disease (GVHD)","volume":"10","author":"Demosthenous","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e26362_bib25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbmt.2016.06.004","article-title":"Augmenting autologous stem cell transplantation to improve outcomes in myeloma","volume":"22","author":"Maybury","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e26362_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e26362_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00348","article-title":"Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities","volume":"4","author":"Botta","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: the green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.heliyon.2024.e26362_bib29","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.3390\/jcm10204717","article-title":"Increased monocytic myeloid-derived suppressor cells in whole blood predict poor prognosis in patients with plasma cell myeloma","volume":"10","author":"Bae","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e26362_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2018.11.002","article-title":"Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway","volume":"442","author":"De Veirman","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2024.e26362_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","article-title":"Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples","volume":"381","author":"Kotsakis","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.heliyon.2024.e26362_bib32","series-title":"PMN-MDSC and Arginase Are Increased in Myeloma and May Contribute to Resistance to Therapy","first-page":"675","volume":"18","author":"Romano","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e26362_bib33","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e26362_bib34","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2024.e26362_bib36","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e26362_bib37","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e26362_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","article-title":"Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2024.e26362_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow V\u03b39V\u03b42 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Castella","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e26362_bib41","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-\u03b2 in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e26362_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000203602","article-title":"Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma","volume":"98","author":"Kr\u00f6ning","year":"1997","journal-title":"Acta Haematol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e26362_bib44","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e26362_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e26362_bib46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1349-7006.2012.02248.x","article-title":"Immunosuppressive activity of CD14+ HLA\u2010DR\u2212 cells in squamous cell carcinoma of the head and neck","volume":"103","author":"Chikamatsu","year":"2012","journal-title":"Cancer Sci."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e26362_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1702464","article-title":"Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor","volume":"261","author":"Gyger","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e26362_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.transci.2006.08.009","article-title":"Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT)","volume":"36","author":"Ergene","year":"2007","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.heliyon.2024.e26362_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5001\/omj.2019.06","article-title":"Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment","volume":"34","author":"Hassan","year":"2019","journal-title":"Oman Med. J."},{"key":"10.1016\/j.heliyon.2024.e26362_bib50","first-page":"324","article-title":"Analysis of factors that influence hematopoietic recovery in autologous transplanted patients with hematopoietic stem cells from peripheral blood, open access maced","volume":"5","author":"Grubovic","year":"2017","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e26362_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4161\/oxim.2.2.8355","article-title":"Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Gon\u00e7alves","year":"2009","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2024.e26362_bib52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2008.12.512","article-title":"Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation","volume":"15","author":"Kim","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e26362_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e26362_bib54","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e26362_bib55","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024023934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024023934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:36:17Z","timestamp":1761784577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024023934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024023934"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26362","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e26362"}}